Literature DB >> 3183949

Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.

M B Spina1, G Cohen.   

Abstract

Incubation of striatal synaptosomes with L-dopa and glucose in either the presence or absence of 10 microM reserpine resulted in a rise in the level of oxidized glutathione (GSSG) within the isolated tissue pellet. The rise in GSSG was concentration dependent in the range of 0.04-1.0 mM L-dopa. With 1.0 mM L-dopa in the presence of reserpine, the GSSG level was elevated by 7.0 +/- 0.7 pmol/mg original striatal tissue, which corresponds to an increase of 38.0 +/- 4.5% compared with control. The rise in GSSG reflects an oxidative stress. The oxidation of dopamine by monoamine oxidase generates H2O2, which is normally detoxified by glutathione peroxidase to yield GSSG. In the presence of clorgyline or pargyline (two monoamine oxidase inhibitors), the rise in GSSG was suppressed by 88-92%, as was the formation of DOPAC. NSD-1055 and carbidopa (two inhibitors of dopa-decarboxylase) also significantly suppressed (50-60%) the rise in GSSG. These data show that the synthesis of dopamine from L-dopa, with subsequent catabolism of dopamine, can evoke a significant rise in the level of GSSG, which reflects the oxidant stress associated with monoamine oxidase activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183949

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.

Authors:  P M Carvey; S Pieri; Z D Ling
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

Authors:  M B Spina; G Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 3.  Melatonin and Parkinson's disease.

Authors:  Juan C Mayo; Rosa M Sainz; Dun-Xian Tan; Isaac Antolín; Carmen Rodríguez; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 4.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Does levodopa accelerate Parkinson's disease?

Authors:  T Simuni; M B Stern
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

6.  Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease.

Authors:  B Drukarch; C A Jongenelen; E Schepens; C H Langeveld; J C Stoof
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

7.  Cloning, sequencing and heterologous expression of the monoamine oxidase gene from Aspergillus niger.

Authors:  B Schilling; K Lerch
Journal:  Mol Gen Genet       Date:  1995-05-20

8.  Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease.

Authors:  Todd B Sherer; Jason R Richardson; Claudia M Testa; Byoung Boo Seo; Alexander V Panov; Takao Yagi; Akemi Matsuno-Yagi; Gary W Miller; J Timothy Greenamyre
Journal:  J Neurochem       Date:  2007-01-04       Impact factor: 5.372

Review 9.  The Magic Velvet Bean of Mucuna pruriens.

Authors:  Lucia Raffaella Lampariello; Alessio Cortelazzo; Roberto Guerranti; Claudia Sticozzi; Giuseppe Valacchi
Journal:  J Tradit Complement Med       Date:  2012-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.